MedTrace Logo

Tocilizumab Plus a Short Prednisone Taper for GCA

NCT03726749 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2022-12-02

Study results available
· View outcomes & findings →

Summary

This is an open-label pilot study of tocilizumab (TCZ) 162 mg weekly administered subcutaneously for 52 weeks in combination with 8 weeks of oral prednisone.

Conditions

  • Giant Cell Arteritis

Interventions

DRUG

Tocilizumab

Tocilizumab is an interleukin-6 (IL-6) receptor inhibitor

DRUG

Prednisone

Prednisone is an anti-inflammatory medication

Sponsors & Collaborators

  • Roche-Genentech

    collaborator INDUSTRY

  • Massachusetts General Hospital

    lead OTHER

Principal Investigators

  • Ana D Fernandes, MA · Massachusetts General Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-11-28
Primary Completion
2021-12-15
Completion
2021-12-29
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03726749 on ClinicalTrials.gov